Standard BioTools Announces Sale of Mass Cytometry Business and Illumina’s Buyout of Contingent Payments to Advance Merger with Treeline Biosciences

Go back to Standard BioTools Announces Sale of Mass Cytometry Business and Illumina’s Buyout of Contingent Payments to Advance Merger with Treeline Biosciences
Labranche & Co (NASDAQ: LAB) Delayed: 0.65 +0.01 (1.56%)
Previous Close $0.64    52 Week High $4.47 
Open $0.63    52 Week Low $3.02 
Day High $0.67    P/E N/A 
Day Low $0.63    EPS $-1.56 
Volume 399,597